

14 January 2021

# By Electronic Lodgement

Market Announcements Office ASX Ltd 20 Bridge Street SYDNEY NSW 2000

Dear Sir/Madam,

# Antipodes Global Investment Company Limited (ASX: APL) – Monthly Investment Update

Please find attached a copy of the investment update for the month ending 31 December 2020.

For further information, please contact 1300 010 311.

Authorised by:

Calvin Kwok Company Secretary



ASX code: APL

MONTHLY COMPANY UPDATE | 31 December 2020

## **Company commentary**

Company performance for the month was -0.3%, underperforming the benchmark which returned -0.1% for the month. The key contributors and detractors are detailed under the Portfolio Commentary section below.

The NTA discount at which the Company's shares trade remained steady at approximately 10% during the month. The combination of improved investment performance of the portfolio and the Conditional Tender Offer (CTO) that if triggered in October 2021, would result in an off market buyback of up to 25% of the Company's shares at post-tax NTA less 2%, are both expected to continue to drive an improvement in the NTA discount during 2021.

The Company wishes shareholders a Happy New Year and thanks shareholders for their support in 2020, a strange year which saw the Company's share price start and end the year at the same level of \$1.04 per share. This 'stability' in the share price masks the volatile global equity market experienced during the year which saw the Company's share price touch a low of \$0.805 on 23rd March 2020 as global markets reacted to the onset of COVID-19. The Company is pleased to report that the Company performance was up 3.5% for the year. Shareholders received a combined interim and final dividend for FY2020, paid during the year of 4.5c per share.

## **Market commentary**

Global equity strength continued in December (+4.6% in USD, -0.1% in AUD following US dollar weakness) as COVID-19 vaccine optimism continued to boost sentiment. Global cyclical stocks outperformed, however investors still exhibited stylistic preference for growth and momentum over low multiple or value - stocks. Materials, Information Technology and Financials outperformed, whilst Utilities and Industrials lagged.

Emerging Markets (+2.5%) broadly outperformed, led by Korea (+11.3%), supported by continued weakness in the US dollar (DXY -2.1%) and optimism over the global economic rebound. China lagged (-0.5%) as the Chinese regulator announced anti-competitive policies and the US added more Chinese companies to a trade blacklist, prohibiting US persons from investing in companies with links to China military.

US equities (-0.6%) marginally underperformed, but were supported by the passage of another \$900bn stimulus package in response to the pandemic and the Fed's commitment to easy policy. Europe (0.0%) performed in line as the UK and EU finalised a Brexit deal, offsetting concerns over further lockdowns as virus cases escalated.

Elsewhere, Brent Crude rose strongly (+8.2% in USD) on demand optimism and Gold (+7.1% in USD) rebounded on higher inflation expectations.

#### Portfolio commentary

Key contributors to performance included:

- Industrials cluster including Siemens and Norsk Hydro, following the outperformance of global cyclicals. Norsk, in particular, has rallied with the ongoing recovery in aluminium prices.
- Connectivity/Compute, notably Samsung Electronics on further evidence of improving supply-demand dynamics in DRAM memory due to limited supply growth, which bodes well for DRAM memory prices in 2021.

 Capital One Financial, Consumer Cyclical Developed Markets (DM), continued its strong performance in a month where US Financials outperformed on the back of rising yields, a successful stimulus package and greater clarity on distributions from the Federal Reserve.

Key detractors to performance included:

- Online Services EM, notably Alibaba and Tencent on continued regulatory pressure to prevent anti-competitive behaviour. We remain constructive on Chinese internet given the growth opportunity for ecommerce in lower tier cities and in new categories, and low penetration of digital ads.
- Healthcare cluster notably Sanofi, which indicated a six-month delay to their (second generation) COVID-19 vaccine to improve the immune response in the elderly.
- ING Groep, Consumer Cyclical DM, fell along with other European banks following the ECB's decision to limit capital distributions, including a recommendation to delay distributions until September 2021.

## Performance (%)<sup>1,2,3</sup>

1 month -0.3 -0.1 -0.2   3 month 9.2 6.5 2.6   Year to date 3.5 5.9 -2.4   1 year 3.5 5.9 -2.4   3 year p.a. 4.7 10.6 -5.9		Company	Benchmark	Difference
Year to date 3.5 5.9 -2.4   1 year 3.5 5.9 -2.4	1 month	-0.3	-O.1	-0.2
1year 3.5 5.9 -2.4	3 month	9.2	6.5	2.6
	Year to date	3.5	5.9	-2.4
3 year p.a. 4.7 10.6 -5.9	1 year	3.5	5.9	-2.4
	3 year p.a.	4.7	10.6	-5.9
Inception p.a. 7.9 12.6 -4.7	Inception p.a.	7.9	12.6	-4.7
Inception 38.1 65.3 -27.2	Inception	38.1	65.3	-27.2

Past performance is not a reliable indicator of future performance. <sup>1</sup> Movement in NTA before tax for the period, adjusted for dividends and income taxes paid and the dilutionary effect of share capital transactions. This figure incorporates underlying portfolio performance net of portfolio related fees and costs, less administration costs of the Company. <sup>2</sup> MSCI All Country World Net Index in AUD (portfolio's benchmark). <sup>3</sup> Inception is 11 October 2016.

## Company performance since inception<sup>1,3</sup>



## Net tangible assets (NTA<sup>5,6</sup>) <sup>4,7</sup>

Pre-tax NTA	Post-tax NTA
\$1.167	\$1.148

<sup>4</sup> These figures are unaudited and approximate only. <sup>5</sup> Pre-tax NTA includes provision for tax on realised gains/losses and other earnings, but excludes any provision for tax on unrealised gains/losses and any deferred tax assets relating to capitalised issue costs and income tax losses. <sup>6</sup> Post-tax NTA includes tax on both realised and unrealised gains/losses and other earnings, and includes deferred tax assets relating to capitalised issue costs and income tax losses.

<sup>7</sup> NTA before tax was \$1.156. This represents the NTA excluding all income tax related assets and liabilities. Company tax of \$0.002 was paid during the month.

## **Dividend history**

	Dividend per share	Ex date	Record date	Payable	% franked
APL	2.5c	08/09/20	09/09/20	30/09/20	50%
APL	2c	05/03/20	06/03/20	27/03/20	50%
APL	2.5c	06/09/19	09/09/19	14/10/19	50%
APL	2c	07/03/19	08/03/19	22/03/19	50%
APL	5c	19/10/18	22/10/18	31/10/18	50%

## Top 10 equity longs

Name	Country	Weight (%)
Électricité de France	France	3.3
Samsung Electronics	Korea	3.0
Ping An Insurance	China/HK	2.9
Microsoft	United States	2.9
Facebook	United States	2.8
Siemens	Germany	2.7
Taiwan Semiconductor	Taiwan	2.6
Capital One Financial	United States	2.5
Volkswagen	Germany	2.4
Merck	United States	2.4

### Asset allocation<sup>8</sup>

	Equities - Long	Other - Long	Equities - Short	Other - Short
Weight (%)	91.1	0.9	-12.0	-4.3
Count	62	1	29	6
Avg. weight (%)	1.5	0.9	-0.4	-0.7
Top 10 (%)	27.5	-	-6.9	-
Top 30 (%)	63.8	-	-	-


<sup>&</sup>lt;sup>8</sup> Non-equity derivatives.

# Regional exposure<sup>9,10</sup> (%)

regional expediate	(70)			
Region	Long	Short	Net	
United States	33.7	-7.9	25.8	
Western Europe	21.8	-1.0	20.8	
- Eurozone	15.8	-0.4	15.4	
- Rest Western Europe	3.9	-	3.9	
- United Kingdom	2.0	-0.6	1.5	
Developed Asia	16.8	-3.2	13.6	
- Korea/Taiwan	10.9	-0.1	10.9	
- Japan	5.8	-3.1	2.7	
Developing Asia	16.2	-	16.2	
- China/Hong Kong	13.4	-	13.4	
- India	2.8	-	2.8	
Australia	2.7	-	2.7	
Total Equities	91.1	-12.0	79.1	
Other	0.9	-4.3	-	
Cash	8.0	-	-	
Totals	100.0	-16.3	-	

<sup>&</sup>lt;sup>9</sup> Where possible, regions, countries and currencies classified on a look through basis. 10 Antipodes classification.

# Sector exposure<sup>10</sup> (%)



Characteristics	
Investment manager	Antipodes Partners Limited
ASX code	APL
Inception date	11 October 2016
Listing date	18 October 2016
Benchmark	MSCI All Country World Net Index in AUD
Management fee	1.10% p.a. <sup>11</sup>
Performance fee	15% of net return in excess of benchmark
Asset value	
Company net tangible assets <sup>4</sup>	\$548m
Market capitalisation	\$496m
Strategy AUM	\$5,856m

<sup>&</sup>lt;sup>11</sup> Inclusive of the net impact of GST and RITC.

## **Company features**

Aims to achieve absolute returns in excess of the benchmark over the investment cycle (typically 3-5 years).

In the absence of finding individual securities that meet minimum riskreturn criteria, cash may be held.

Equity shorts and currency positions used to take advantage of attractive risk-return opportunities, offset specific long portfolio risks and provide some protection from negative tail risk. Derivatives may also be used to amplify high conviction ideas.

Typical net equity exposure of 50% to 100%; maximum allowable gross exposure limit of 150% of NAV.

## **About the Manager**



**Jacob Mitchell** Chief Investment Officer Lead Portfolio Manager

Antipodes Partners Limited is an award-winning global asset manager offering a fundamental, value-focused investment approach founded in 2015 by Jacob Mitchell, formerly Deputy Chief Investment Officer of Platinum Asset Management, together with a number of former colleagues and like-minded value investors.

Antipodes is majority owned by its investment team and its performance culture is underpinned by sensible incentives, a focused offering and the outsourcing of non-investment functions to minority partner Pinnacle Investment Management Limited.



### **Further information**

**1300 010 311** 

invest@antipodespartners.com

**Antipodes Partners Limited** Level 35, 60 Margaret St Sydney NSW 2000 Australia

antipodespartners.com/apl

#### Disclaimer

Antipodes Partners Limited (ABN 29 602 042 035, AFSL 481 580) ('Antipodes Partners', 'Antipodes') is the investment manager of Antipodes Global Investment Company Limited ABN 38 612 843 517 ('APL' or the 'Company').

Antipodes Global Investment Company (ACN 612 843 517) is the issuer of the shares in the Company under the Offer Document. Any offer or sale of securities are made pursuant to definitive documentation, which describes the terms of the offer ('Offer Document') available at www.antipodespartners.com/apl.

Any potential investor should consider the relevant Offer Document before deciding whether to acquire, or continue to hold units in, an investment. Past performance is for illustrative purposes only and is not indicative of future performance. This communication is for general information only and was prepared for multiple distribution. This communication is not, and does not constitute, an offer to sell or the solicitation, invitation or recommendation to purchase any securities and neither this communication nor anything contained in it forms the basis of any contract or commitment. Prospective investors who want to acquire under the offer will need to complete an application form that is in or accompanies the Offer Document. The Offer Document is an important document that should be read in its entirety before deciding whether to participate in the offer. Prospective investors should rely only on information in the Offer Document and any supplementary or replacement document. Prospective investors should contact their professional advisers with any queries after reading the Offer Document.

Whilst APL and Antipodes Partners believe the information contained in this communication is reliable, no warranty is given as to its accuracy, reliability or completeness and persons relying on this information do so at their own risk. Subject to any liability which cannot be excluded under the relevant laws, APL and Antipodes Partners disclaim all liability to any person relying on the information contained in this communication in respect of any loss or damage (including consequential loss or damage), however caused, which may be suffered or arise directly or indirectly in respect of such information.

The information is not intended as a securities recommendation or statement of opinion intended to influence a person or persons in making a decision in relation to investment. The information in this communication has been prepared without taking account of any person's objectives, financial situation or needs. Any persons relying on this information should obtain professional advice before doing so. The issuer is not licensed to provide financial product advice. Please consult your financial adviser before making a decision. Any opinions and forecasts reflect the judgment and assumptions of APL and Antipodes Partners and its representatives on the basis of information at the date of publication and may later change without notice. Any projections contained in this presentation are estimates only and may not be realised in the future. The information is not intended as a securities recommendation or statement of opinion intended to influence a person or persons in making a decision in relation to investment. Unauthorised use, copying, distribution, replication, posting, transmitting, publication, display, or reproduction in whole or in part of the information contained in this communication is prohibited without obtaining prior written permission from APL and Antipodes Partners.

The Zenith Investment Partners ("Zenith") Australian Financial Services License No. 226872 rating (Antipodes Global Investment Company Limited rating issued May 2019) referred to in this document is limited to "General Advice" (as defined by the Corporations Act 2001) for Wholesale clients only. This advice has been prepared without taking into account the objectives, financial situation or needs of any individual. It is not a specific recommendation to purchase, sell or hold the relevant product(s). Investors should seek independent financial advice before making an investment decision and should consider the appropriateness of this advice in light of their own objectives, financial situation and needs. Investors should obtain a copy of, and consider the PDS or offer document before making any decision and refer to the full Zenith Product Assessment available on the Zenith website. Zenith usually charges the product issuer, fund manager or a related party to conduct Product Assessments. Full details regarding Zenith's methodology, ratings definitions and regulatory compliance are available on our Product Assessment's and at http://www.zenithpoartners.com.au/RegulatoryGuidelines